Olympus–Swan Deal Highlights Rise of Build-to-Buy in Robotic Surgery and Medtech

Olympus Corporation and Revival Healthcare Capital made headlines this week by formalizing a build-to-buy agreement. Under the terms, Olympus gains exclusive rights to acquire Swan EndoSurgical, a company it co-incubated with Revival to develop a next-generation robotic platform for endoluminal surgery.

The potential price tag? Up to $458 million, starting with a $65 million initial investment from Olympus. The deal positions Olympus to expand into high-value gastrointestinal (GI) interventions while reducing the risk typically associated with acquiring early-stage technologies.

Why Build-to-Buy Deals Are Gaining Momentum

Build-to-buy partnerships, also known as structured deals or option-to-acquire models, have been part of medtech for years, but they are now emerging as a preferred approach for capital-efficient innovation. In these arrangements, a strategic partner invests in a startup early, offering not just financial backing but also clinical, regulatory, and commercial expertise. The strategic retains the right, though not the obligation, to acquire the startup at a later date.

This approach offers benefits to all parties. For strategics, it enables them to evaluate technologies up close before committing to a full acquisition, mitigating both financial and integration risks. Startups gain stability, clear exit visibility, and access to expertise they might not otherwise have, all while maintaining operational autonomy. Investors see a de-risked path to liquidity with a buyer already in place.

When structured effectively, the build-to-buy model aligns incentives. Startups advance toward commercialization, strategics secure a vetted innovation pipeline, and investors can plan exits with greater certainty.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/olympus-swan-deal-highlights-rise-of-build-to-buy-in-robotic-surgery-and-medtech

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more